Product logins

Find logins to all Clarivate products below.


Obesity / Overweight – Epidemiology – Middle East & Africa

Clarivate Epidemiology’s coverage of obesity / overweight comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of obesity / overweight for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

Clarivate Epidemiology’s obesity / overweight forecast will answer the following questions:

  • Of all people with obesity / overweight, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of obesity / overweight over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 10 obesity/overweight patient populations, as follows:

  • Diagnosed prevalent cases of obesity / overweight.
  • Undiagnosed prevalent cases of obesity / overweight.
  • Total prevalent cases of obesity.
  • Total prevalent cases of class I obesity.
  • Total prevalent cases of class II obesity.
  • Total prevalent cases of class III obesity.
  • Total prevalent cases of overweight.
  • Drug-treatable prevalent cases of overweight.
  • Diagnosed drug-treated prevalent cases of obesity.
  • Diagnosed non-drug-treated prevalent cases of obesity.

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Hyperkalemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hyperkalemia (US)
Hyperkalemia is a potentially life-threatening condition characterized by a serum potassium concentration that exceeds 5.5 mEq/L. Despite various guidelines, a universally accepted consensus on the…
Report
Primary Biliary Cholangitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Primary Biliary Cholangitis (US)
Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation and progressive damage to intrahepatic bile ducts, leading to bile buildup, followed by…
Report
Emerging Vaccines – Landscape & Forecast – Disease Landscape & Forecast (G7)
Vaccination programs have had a revolutionary impact on global public health, not only dramatically reducing the incidence of infectious disease but also reducing childhood and adult mortality and…
Report
Chronic Obstructive Pulmonary Disease – Landscape & Forecast – Disease Landscape & Forecast (G7)
The chronic obstructive pulmonary disease (COPD) market continues to gradually shift away from LABA/ICS FDCs toward LABA/LAMA FDCs and LABA/LAMA/ICS FDCs, but current and emerging generics are…
Report
Schizophrenia – Landscape & Forecast – Disease Landscape & Forecast (G7)
The schizophrenia therapy market remains very competitive; atypical and typical antipsychotics play a dominant role. While the continued generic erosion of atypical antipsychotics influences…